While the world has been working toward an HIV vaccine for years, some important strides have been made recently in clinical research.
Two trials are to begin in South Africa in 2016, both evaluating whether antibodies in the blood can prevent HIV infection. One study, HVTN 702, uses active immunization, while the other, AMP, uses passive immunization.
Read more about these trials here.
Be part of our network of leaders and innovators.Join now